Test Code 604
Test Details
Myeloperoxidase (MPO)
MPO is an enzyme found in circulating white blood cells (neutrophils) and is also produced by white blood cells (monocytes) in the foam cells within the artery wall. Elevated levels of MPO may indicate the presence of unstable plaque or buildup in the arterial wall and an increased risk of plaque rupture. In patients with high levels of MPO, careful evaluation of CVD risk should be considered by the healthcare professional.
Methodology
Enzyme immunoassay
Patient Preparation
None
Preferred Specimen
1.0 mL EDTA plasma collected in plasma separator tube (Pearl Top)
Alternate Specimen
None
Transport Temperature
Refrigerated (ship on frozen cold packs)
Stability
Refrigerated: 4 days
Lab Values
Myeloperoxidase (MPO)
- Optimal: <470 pmol/L
- Borderline: 470-539 pmol/L
- Increased Risk: ≥540 pmol/L
- Alert: >1658 pmol/L
Clinical Significance
Myeloperoxidase (MPO)
- Elevated MPO levels have been shown to be a significant independent risk factor for a major adverse cardiac event (MACE) over the ensuing one to six months.1
References:
- Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349(17):1595-1604.
Treatment Options
Myeloperoxidase (MPO)
- Evaluate cardiovascular disease (CVD) status with physical exam, stress testing and other CVD diagnostic modalities.
- Modify all existing CVD risk factors.
- Medications to reduce elevated MPO levels may include:
- Statins
- Beta-blockers
- Angiotensin enzyme converting inhibitors
